A Study of the Use of Text Message Reminders to Take Palbociclib

Memorial Sloan Kettering Cancer Center (MSK)

Status: Active, not recruiting

Conditions: Breast Cancer

Treatments: Other: OhMD APP; Other: Paper Drug Diary

Study type: Interventional

Funder types: Other

Identifiers

NCT04216576

19-458

Details and patient eligibility

About

The purpose of this study is to find out whether it is feasible (acceptable to participants) to use a smartphone app to send text message reminders to take palbociclib, and whether these reminders are effective at helping people remember to take palbociclib according to the treatment schedule.

Enrollment: 45 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a breast cancer diagnosis who are initiating therapy on palbociclib (Ibrance)
• >/= 18 years of age
• Able to speak, read and write English
• Willingness and ability to send and receive text messages with intervention app
• Own a mobile telephone "smartphone" with text messaging capabilities. Only iPhone or Android operating systems support OhMD Application
• Criteria applicable for both Control and Intervention groups
• Flip-phones do not support OhMD Application and thus ineligible to participate
• Initiation palbociclib (Ibrance) for the first time, either as monotherapy or in conjunction with other medication such as Lstrozole (Femara) or Fulvestrant (Faslodex)

Exclusion criteria

• History of taking palbociclib (Ibrance)
• Patients whose caregivers coordinate their health care

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

45 participants in 2 patient groups

Standard of Care

Active Comparator group

Description:

Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care

Treatment:

Other: Paper Drug Diary

Standard of Care + Intervention

Experimental group

Description:

Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care + unidirectional text messaging intervention

Treatment:

Other: OhMD APP